Closet wrote, I believe not for the first time, th
Post# of 148286
Quote:
The FDA has not seen the data from the S/C trial
But it would only make sense for the FDA to allow extended use of Leronlimab for severe to critical patients, as they are doing here, if they've seen at least partial results of the interim analysis. And those results must have been good.
The FDA seems to be indicating that they expect to approve Leron. Due to the information they have so far.